{"pmid":32455499,"title":"Late onset of acral necrosis after SARS-CoV-2 infection resolution.","text":["Late onset of acral necrosis after SARS-CoV-2 infection resolution.","SARS-CoV-2 has been hypothesized as the aetiologic agent of CLL, on the basis of the temporal correlation between the \"burst\" of skin manifestations and the viral pandemic, even though we have scarce evidence of swab-confirmed infections. Authors have therefore suggested some pathogenetic mechanisms such as a delayed immune-mediated reaction to the virus in genetically-predisposed patients(1) or an early IFN-I response in young patients, muting early viral replication but also inducing microangiopathic changes.","J Eur Acad Dermatol Venereol","Balestri, R","Termine, S","Rech, G","Girardelli, C R","32455499"],"abstract":["SARS-CoV-2 has been hypothesized as the aetiologic agent of CLL, on the basis of the temporal correlation between the \"burst\" of skin manifestations and the viral pandemic, even though we have scarce evidence of swab-confirmed infections. Authors have therefore suggested some pathogenetic mechanisms such as a delayed immune-mediated reaction to the virus in genetically-predisposed patients(1) or an early IFN-I response in young patients, muting early viral replication but also inducing microangiopathic changes."],"journal":"J Eur Acad Dermatol Venereol","authors":["Balestri, R","Termine, S","Rech, G","Girardelli, C R"],"date":"2020-05-27T11:00:00Z","year":2020,"_id":"32455499","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1111/jdv.16668","keywords":["acro-ischemia","covid-19","sars-cov-2","acral necrosis"],"topics":["Case Report"],"weight":1,"_version_":1667881798490652674,"score":9.490897,"similar":[{"pmid":32390279,"title":"Cutaneous Signs in COVID-19 Patients: A Review.","text":["Cutaneous Signs in COVID-19 Patients: A Review.","COVID-19 pandemic caused by beta-coronavirus SARS-CoV-2 primarily affects the epithelium of the airways. With the increasing involvement of dermatologist in management of this crisis, cutaneous symptoms gained more and more attention. In this review we will describe cutaneous symptoms of patients of all ages in association with COVID-19. We will focus on such disorders that are caused by direct action of the SARS-CoV-2 virus on tissues, complement and coagulation system and on non-specific eruption of the systemic viral infection. Drug-induced reactions are only mentioned in the differential diagnoses. Although more systematic investigations are warranted, it comes clear that some symptoms are clinical signs of a milder COVID-19 course, while others are a red flag for a more severe course. Knowledge of the cutaneous manifestations of COVID-19 may help in early diagnosis, triage of patients and risk stratification. This article is protected by copyright. All rights reserved.","Dermatol Ther","Wollina, Uwe","Karadag, Ayse Serap","Rowland-Payne, Christopher","Chiriac, Anca","Lotti, Torello","32390279"],"abstract":["COVID-19 pandemic caused by beta-coronavirus SARS-CoV-2 primarily affects the epithelium of the airways. With the increasing involvement of dermatologist in management of this crisis, cutaneous symptoms gained more and more attention. In this review we will describe cutaneous symptoms of patients of all ages in association with COVID-19. We will focus on such disorders that are caused by direct action of the SARS-CoV-2 virus on tissues, complement and coagulation system and on non-specific eruption of the systemic viral infection. Drug-induced reactions are only mentioned in the differential diagnoses. Although more systematic investigations are warranted, it comes clear that some symptoms are clinical signs of a milder COVID-19 course, while others are a red flag for a more severe course. Knowledge of the cutaneous manifestations of COVID-19 may help in early diagnosis, triage of patients and risk stratification. This article is protected by copyright. All rights reserved."],"journal":"Dermatol Ther","authors":["Wollina, Uwe","Karadag, Ayse Serap","Rowland-Payne, Christopher","Chiriac, Anca","Lotti, Torello"],"date":"2020-05-12T11:00:00Z","year":2020,"_id":"32390279","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1111/dth.13549","keywords":["acro-ischemia","androgenetic alopecia","covid-19","chilblain-like eruptions","maculopapular rash","purpuric rash","sars-cov-2","urticaria"],"topics":["Diagnosis"],"weight":1,"_version_":1666528580020994048,"score":99.27515},{"pmid":32460624,"title":"The amount of cytokine-release defines different shades of Sars-Cov2 infection.","text":["The amount of cytokine-release defines different shades of Sars-Cov2 infection.","The recent outbreak of coronavirus disease (COVID 19), spreading from China all around the world in early 2020, has led scientists to investigate the immuno-mediated mechanisms underlying the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2) infection. Depending on the amount of cytokines released as the result of the immunological activation induced by SARS-CoV2, three major clinical phenotypes can be identified: \"mild\",symbolized as a \"drizzle\" of cytokines, severe as a \"storm\", and critical as a \"hurricane\". In patients with mild symptoms, the release of pro-inflammatory cytokines is balanced to obtain a defense response against the virus which is often self-limiting and overcomes without tissue damage. In severe phenotype, resembling a \"cytokine-release syndrome\", SARS-CoV2 causes the lysis of the immune-mediators leading to a cytokine storm able to induce lung epithelium damage and acute respiratory distress syndrome. In critical patients, the immune response may become uncontrolled, thus the cytokine burst resembles a form of secondary hemophagocytic lymphohistiocytosis which may result in a multi organ failure. In addition to the standard of care, an immune-modulatory therapy tailored to each one of the different phenotypes should be used in order to prevent or reduce the release of cytokines responsible for organ damage and disease progression.","Exp Biol Med (Maywood)","Bindoli, S","Felicetti, M","Sfriso, P","Doria, A","32460624"],"abstract":["The recent outbreak of coronavirus disease (COVID 19), spreading from China all around the world in early 2020, has led scientists to investigate the immuno-mediated mechanisms underlying the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2) infection. Depending on the amount of cytokines released as the result of the immunological activation induced by SARS-CoV2, three major clinical phenotypes can be identified: \"mild\",symbolized as a \"drizzle\" of cytokines, severe as a \"storm\", and critical as a \"hurricane\". In patients with mild symptoms, the release of pro-inflammatory cytokines is balanced to obtain a defense response against the virus which is often self-limiting and overcomes without tissue damage. In severe phenotype, resembling a \"cytokine-release syndrome\", SARS-CoV2 causes the lysis of the immune-mediators leading to a cytokine storm able to induce lung epithelium damage and acute respiratory distress syndrome. In critical patients, the immune response may become uncontrolled, thus the cytokine burst resembles a form of secondary hemophagocytic lymphohistiocytosis which may result in a multi organ failure. In addition to the standard of care, an immune-modulatory therapy tailored to each one of the different phenotypes should be used in order to prevent or reduce the release of cytokines responsible for organ damage and disease progression."],"journal":"Exp Biol Med (Maywood)","authors":["Bindoli, S","Felicetti, M","Sfriso, P","Doria, A"],"date":"2020-05-29T11:00:00Z","year":2020,"_id":"32460624","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1177/1535370220928964","keywords":["covid-19","crs","hlh/mas","sars-cov2","cytokines"],"locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1668079521491845120,"score":97.85104},{"pmid":32421877,"title":"A late onset widespread skin rash in a previous Covid-19 infected patient: viral or multidrug effect?","text":["A late onset widespread skin rash in a previous Covid-19 infected patient: viral or multidrug effect?","in the end of 2019, a series of pneumonia cases emerged in China, with clinical presentations greatly resembling viral pneumonia, caused by Covid-19 o SARS-CoV-2. Currently, several clinicians described an increasingly cases of coronavirus-positive patients reporting skin problems, either in early stage of infection or as late onset manifestation. Recently, Dr. Sebastiano Recalcati analyzed the cutaneous involvement in 148 COVID-19 patients hospitalized in the Lecco Hospital, Lombardy, Italy.","J Eur Acad Dermatol Venereol","Skroza, N","Bernardini, N","Balduzzi, V","Mambrin, A","Marchesiello, A","Michelini, S","Tolino, E","Proietti, I","Di Cristofano, C","Petrozza, V","Potenza, C","32421877"],"abstract":["in the end of 2019, a series of pneumonia cases emerged in China, with clinical presentations greatly resembling viral pneumonia, caused by Covid-19 o SARS-CoV-2. Currently, several clinicians described an increasingly cases of coronavirus-positive patients reporting skin problems, either in early stage of infection or as late onset manifestation. Recently, Dr. Sebastiano Recalcati analyzed the cutaneous involvement in 148 COVID-19 patients hospitalized in the Lecco Hospital, Lombardy, Italy."],"journal":"J Eur Acad Dermatol Venereol","authors":["Skroza, N","Bernardini, N","Balduzzi, V","Mambrin, A","Marchesiello, A","Michelini, S","Tolino, E","Proietti, I","Di Cristofano, C","Petrozza, V","Potenza, C"],"date":"2020-05-19T11:00:00Z","year":2020,"_id":"32421877","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1111/jdv.16633","keywords":["covid-19","sars-cov-2","adverse drug reaction","infection","skin manifestation","urticarial vasculitis"],"locations":["China","Lombardy","Italy"],"countries":["China","Italy"],"countries_codes":["CHN|China","ITA|Italy"],"topics":["Treatment"],"weight":1,"_version_":1667254896786669569,"score":91.913506},{"pmid":32504923,"title":"N-Acetylcysteine: A potential therapeutic agent for SARS-CoV-2.","text":["N-Acetylcysteine: A potential therapeutic agent for SARS-CoV-2.","COVID-19, a respiratory disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), continues to spread across the globe. Predisposing factors such as age, diabetes, cardiovascular disease, and lowered immune function increase the risk of disease severity. T cell exhaustion, high viral load, and high levels of TNF-a, IL1beta, IL6, IL10 have been associated with severe SARS-CoV-2. Cytokine and antigen overstimulation are potentially responsible for poor humoral response to the virus. Lower cellular redox status, which leads to pro-inflammatory states mediated by TNF-a is also potentially implicated. In vivo, in vitro, and human clinical trials have demonstrated N-acetylcysteine (NAC) as an effective method of improving redox status, especially when under oxidative stress. In human clinical trials, NAC has been used to replenish glutathione stores and increase the proliferative response of T cells. NAC has also been shown to inhibit the NLRP3 inflammasome pathway (IL1beta and IL18) in vitro, and decrease plasma TNF-a in human clinical trials. Mediation of the viral load could occur through NAC's ability to increase cellular redox status via maximizing the rate limiting step of glutathione synthesis, and thereby potentially decreasing the effects of virally induced oxidative stress and cell death. We hypothesize that NAC could act as a potential therapeutic agent in the treatment of COVID-19 through a variety of potential mechanisms, including increasing glutathione, improving T cell response, and modulating inflammation. In this article, we present evidence to support the use of NAC as a potential therapeutic agent in the treatment of COVID-19.","Med Hypotheses","Poe, Francis L","Corn, Joshua","32504923"],"abstract":["COVID-19, a respiratory disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), continues to spread across the globe. Predisposing factors such as age, diabetes, cardiovascular disease, and lowered immune function increase the risk of disease severity. T cell exhaustion, high viral load, and high levels of TNF-a, IL1beta, IL6, IL10 have been associated with severe SARS-CoV-2. Cytokine and antigen overstimulation are potentially responsible for poor humoral response to the virus. Lower cellular redox status, which leads to pro-inflammatory states mediated by TNF-a is also potentially implicated. In vivo, in vitro, and human clinical trials have demonstrated N-acetylcysteine (NAC) as an effective method of improving redox status, especially when under oxidative stress. In human clinical trials, NAC has been used to replenish glutathione stores and increase the proliferative response of T cells. NAC has also been shown to inhibit the NLRP3 inflammasome pathway (IL1beta and IL18) in vitro, and decrease plasma TNF-a in human clinical trials. Mediation of the viral load could occur through NAC's ability to increase cellular redox status via maximizing the rate limiting step of glutathione synthesis, and thereby potentially decreasing the effects of virally induced oxidative stress and cell death. We hypothesize that NAC could act as a potential therapeutic agent in the treatment of COVID-19 through a variety of potential mechanisms, including increasing glutathione, improving T cell response, and modulating inflammation. In this article, we present evidence to support the use of NAC as a potential therapeutic agent in the treatment of COVID-19."],"journal":"Med Hypotheses","authors":["Poe, Francis L","Corn, Joshua"],"date":"2020-06-07T11:00:00Z","year":2020,"_id":"32504923","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1016/j.mehy.2020.109862","keywords":["covid-19","coronavirus","glutathione","n-acetylcysteine","nac","nlrp3","oxidative stress","redox potential","redox status","sars-cov-2","t cell exhaustion","tnf-a"],"locations":["Cytokine","vivo"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1668892488363933696,"score":90.403625},{"pmid":32409976,"title":"Follow-up of skin lesions during the evolution of COVID-19: a case report.","text":["Follow-up of skin lesions during the evolution of COVID-19: a case report.","The disease caused by the new coronavirus (COVID-19) has many systemic manifestations affecting the upper airways, lungs, gastrointestinal tract and inducing hematological repercussions. With the evolution of the pandemic, skin lesions were observed. However, there is little information about the evolution of the lesions at this moment. The authors report a case of a patient who had more than one exposure to the coronavirus during the evolution of the disease and manifested different types of edematous lesions. The lesions started in the prodromal period and changed their presentation and localization during the evolution of COVID-19. The lesions regressed quickly with the use of corticoid cream and antihistamine. Viral skin lesions are frequent causes of exanthema. However, viral etiology is not always investigated in acute urticarial and atypical erythematous-edematous conditions. The immunological basis of acute urticaria has points in common with COVID-19, justifying the appearance of lesions. Investigation of viral etiology should always be remembered in acute urticarial and edematous conditions.","Arch Dermatol Res","de Medeiros, Vanessa Lucilia Silveira","Silva, Lucas Fagundes Teixeira","32409976"],"abstract":["The disease caused by the new coronavirus (COVID-19) has many systemic manifestations affecting the upper airways, lungs, gastrointestinal tract and inducing hematological repercussions. With the evolution of the pandemic, skin lesions were observed. However, there is little information about the evolution of the lesions at this moment. The authors report a case of a patient who had more than one exposure to the coronavirus during the evolution of the disease and manifested different types of edematous lesions. The lesions started in the prodromal period and changed their presentation and localization during the evolution of COVID-19. The lesions regressed quickly with the use of corticoid cream and antihistamine. Viral skin lesions are frequent causes of exanthema. However, viral etiology is not always investigated in acute urticarial and atypical erythematous-edematous conditions. The immunological basis of acute urticaria has points in common with COVID-19, justifying the appearance of lesions. Investigation of viral etiology should always be remembered in acute urticarial and edematous conditions."],"journal":"Arch Dermatol Res","authors":["de Medeiros, Vanessa Lucilia Silveira","Silva, Lucas Fagundes Teixeira"],"date":"2020-05-16T11:00:00Z","year":2020,"_id":"32409976","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1007/s00403-020-02091-0","keywords":["covid-19","emergent infections","sars-cov-2","skin","urticaria","virus"],"topics":["Case Report"],"weight":1,"_version_":1666897318908002304,"score":89.41833}]}